Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma
Clinical trial NCT05189093 · COMPLETED
Trial details
- NCT number
- NCT05189093
- Sponsor
- Hangzhou Hanx Biopharmaceuticals, Ltd.
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-31
- Primary completion
- 2025-06-25
- Enrollment
- 48
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.